APA (7th ed.) Citation

Nakajima, A., Yamanaka, T., Yamamoto, K., Honda, Y., Imajo, K., Yoneda, M., . . . Wada, K. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Nakajima, Atsushi, et al. Rationale and Design of a Randomised, Double-blind, Placebo-controlled, Parallel-group, Investigator-initiated Phase 2a Study to Investigate the Efficacy and Safety of Elobixibat in Combination with Cholestyramine for Non-alcoholic Fatty Liver Disease. BMJ Publishing Group.

MLA (9th ed.) Citation

Nakajima, Atsushi, et al. Rationale and Design of a Randomised, Double-blind, Placebo-controlled, Parallel-group, Investigator-initiated Phase 2a Study to Investigate the Efficacy and Safety of Elobixibat in Combination with Cholestyramine for Non-alcoholic Fatty Liver Disease. BMJ Publishing Group.